K.J. Harrison & Partners’s Intellia Therapeutics NTLA Stock Holding History

K.J. Harrison & Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,045	Closed	-$265K	–	172
2019 Q4	$265K	Hold	18,045	–	–	0.07%	169
2019 Q3	$241K	Hold	18,045	–	–	0.07%	152
2019 Q2	$295K	Hold	18,045	–	–	0.09%	130
2019 Q1	$308K	Hold	18,045	–	–	0.11%	129
2018 Q4	$246K	Sell	18,045 -13,500	-43%	-$251K	0.15%	102
2018 Q3	$903K	Hold	31,545	–	–	0.23%	116
2018 Q2	$863K	Buy	+31,545	New	+$764K	0.25%	111
2018 Q1	–	Sell	-16,020	Closed	-$308K	–	186
2017 Q4	$308K	Buy	+16,020	New	+$370K	0.1%	144

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

K.J. Harrison & Partners's NTLA Position: Q1 2020 in Review

K.J. Harrison & Partners sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 18,045 shares — an estimated $265K sold.

K.J. Harrison & Partners first reported a position in NTLA in Q4 2017 and held it in 8 quarters. The position peaked at $903K in Q3 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

K.J. Harrison & Partners reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
K.J. Harrison & Partners sold 18,045 Intellia Therapeutics shares in Q1 2020, an estimated $265K.
K.J. Harrison & Partners first reported a position in Intellia Therapeutics in Q4 2017 and held it in 8 quarters.
K.J. Harrison & Partners's Intellia Therapeutics position peaked at $903K in Q3 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on K.J. Harrison & Partners's 13F filing for Q1 2020, filed 5 May 2020.